Avacta Life Sciences Limited
  • About
  • Therapeutics
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • Group Team
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
    • Diagnostics
    • Our Brands
    • Affimer®
    • Team
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Research
  • News
  • Careers
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Group Team
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
    • Diagnostics
    • Our Brands
    • Affimer®
    • Team
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Research
  • News
  • Careers
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News Investors Page 2
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

Investors

21 Jun 2023

Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study

Investors | Therapeutics
19 Jun 2023

Director Appointment

Investors
19 Jun 2023

Statement regarding market speculation

Investors
08 Jun 2023

Avacta Annual General Meeting and Shareholder Event Detailed Agenda

Investors
05 Jun 2023

Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake

Investors | Therapeutics
02 Jun 2023

Posting of Annual Report and Notice of AGM

Investors
01 Jun 2023

Avacta acquires Coris Bioconcept, adding a broad range of marketed professional-use rapid tests to the Group

Diagnostics | Investors
27 Apr 2023

First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study

Investors | Therapeutics
24 Apr 2023

Preliminary Results for the year ended 31 December 2022

Investors
21 Apr 2023

Issue of Equity and Total Voting Rights

Investors

Posts navigation

Older posts
Newer posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

Consilium
Strategic Communications
85 Gresham Street
London
EC2V 7NQ

Email

Twitter | Linkedin

©2023 Avacta Life Sciences Limited. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok